Back to top
more

Accuray (ARAY)

(Delayed Data from NSDQ)

$1.67 USD

1.67
1,168,378

-0.07 (-4.02%)

Updated Sep 19, 2025 04:00 PM ET

After-Market: $1.66 -0.01 (-0.60%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.64%
2Buy17.83%
3Hold9.69%
4Sell5.29%
5Strong Sell2.54%
S&P50011.29%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (92 out of 245)

Industry: Medical - Instruments

Zacks News

Zacks Equity Research

Accuray Radixact Picked by India's Apollo for Cancer Treatment

Accuray's (ARAY) flagship Radixact radiotherapy platform to help in cancer treatment at Apollo Hospital Group in New Delhi and Chennai, India.

    Zacks Equity Research

    Accuray's CyberKnife Treats First Patient at Erasmus MC

    Accuray (ARAY) and Erasmus MC partner to develop CyberKnife platform to simplify diagnosis of oligometastatic diseases.

      Zacks Equity Research

      Accuray Banks on Acquisition & Partnership Amid Competition

      Accuray's (ARAY) partnerships with Premier and Amerinet are expected to help the company gain significant penetration in hospitals and oncology centers.

        Zacks Equity Research

        Varian Medical Receives Regulatory Nod for Sirtex Buyout

        The acquisition of Sirtex will fortify Varian Medical's (VAR) footprint in Australia. The transaction is likely to close in late May 2018.

          Sanghamitra Saha headshot

          Here's Why Small-Cap HealthCare ETFs & Stocks Are Good Picks

          Two reasons why small-cap healthcare stocks and ETFs could be winners in the coming days.

            Zacks Equity Research

            Accuray Gains on Radixact Unit, Solid Geographical Foothold

            Radixact and TomoTherapy along with solid global prospects are the key catalysts for Accuray (ARAY).

              Zacks Equity Research

              Cogentix Medical (CGNT) Looks Good: Stock Adds 13.3% in Session

              The shares of Cogentix Medical (CGNT) rose over 13% yesterday after reports surfaced that the company is going to be acquired by Laborie Medical Technologies.

                Zacks Equity Research

                Why Is Accuray (ARAY) Down 8% Since its Last Earnings Report?

                Accuray (ARAY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                  Zacks Equity Research

                  AmerisourceBergen (ABC) Beats on Q1 Earnings, FY18 View Up

                  Strong Growth in Pharmaceutical Distribution Segment and World Courier business drove AmerisourceBergen (ABC) in Q1.

                    Zacks Equity Research

                    Becton, Dickinson (BDX) Beats on Q1 Earnings, Guidance Solid

                    Strong growth in BD Medical and BD Life sciences segments drove Becton, Dickinson's (BD) top line in Q1.

                      Zacks Equity Research

                      athenahealth (ATHN) Tops Earnings & Revenue Estimates in Q4

                      Strong growth in Business and Services segment drove athenahealth's (ATHN) top line in Q4.

                        Zacks Equity Research

                        Pacific Biosciences (PACB) Q4 Loss Narrows, Consumables Up

                        Pacific Biosciences' (PACB) consumable revenue platform proves a vital growth-driver in Q4. Sales momentum in China remains robust.

                          Zacks Equity Research

                          Quest Diagnostics (DGX) Tops Q4 Earnings, 2018 View Strong

                          Quest Diagnostics' (DGX) year-over-year revenue improvement in Q4 came on the back of successful execution of its two-point strategy of accelerating growth and driving operational excellence.

                            Zacks Equity Research

                            Boston Scientific (BSX) Q4 Earnings In Line, Revenues Top

                            In Q4, Boston Scientific (BSX) registers balanced growth across all business lines and geographies.

                              Zacks Equity Research

                              Conmed (CNMD) Beats Earnings and Revenue Estimates in Q4

                              Conmed (CNMD) benefits from impressive general surgery performance and enhanced innovation in Q4.

                                Zacks Equity Research

                                McKesson (MCK) Beats on Q3 Earnings & Revenues, Ups '18 View

                                Strong Performance in Distribution Solutions segment drives McKesson (MCK) in Q3. An impressive FY18 outlook instills investor's optimism.

                                  Zacks Equity Research

                                  Baxter (BAX) Beats on Q4 Earnings & Revenues, '18 View Solid

                                  Strong performance in the Hospital Products and Renal Products segments drives Baxter (BAX) in Q4.

                                    Zacks Equity Research

                                    IDEXX Laboratories (IDXX) Beats on Q4 Earnings and Revenues

                                    IDEXX (IDXX) rides high on strength in CAG business in Q4. A raised guidance buoys optimism.

                                      Zacks Equity Research

                                      4 Reasons Why You Should Buy Accuray (ARAY) Stock Right Now

                                      Accuray (ARAY) rides high on its Radixact platform and latest software overhaul.

                                        Zacks Equity Research

                                        Zacks.com highlights: Accuray, Berkshire Hills Bancorp, A. Schulman, Sysco and Tailored Brands

                                        Zacks.com highlights: Accuray, Berkshire Hills Bancorp, A. Schulman, Sysco and Tailored Brands

                                          Zacks Equity Research

                                          QIAGEN (QGEN) Beats on Q4 Earnings and Revenues, Issues View

                                          QIAGEN's (QGEN) year-over-year growth in Q4 revenues is encouraging. Expansion in operating margin buoys optimism.

                                            Zacks Equity Research

                                            Thermo Fisher (TMO) Q4 Earnings Beat on Growth in All Lines

                                            Thermo Fisher (TMO) registers a solid international performance in Q4 with strong year-over-year growth in the Asia-Pacific and the emerging markets of China, South Korea and the Middle East.

                                              Zacks Equity Research

                                              Stryker (SYK) Beats Earnings and Revenue Estimates in Q4

                                              Stryker's (SYK) Q4 results benefit from Mako product platform and higher organic sales.

                                                Zacks Equity Research

                                                Illumina (ILMN) Tops Q4 Earnings & Revenues, Issues Guidance

                                                Illumina (ILMN) gains from strength in sequencing consumables and instruments as well as microarray portfolios in Q4.

                                                  Zacks Equity Research

                                                  Align Technology (ALGN) Q4 Earnings Top on Invisalign Sales

                                                  Align Technology (ALGN) gains on solid contributions from the Clear Aligner as well as Scanner and Service segments in Q4.